AndreaBozzo/ceres-open-data-index huggingface dataset:
High-pressure biotechnology in medicine and pharmaceutical science

High-pressure (HP) biotechnology is an emerging technique
initially applied for food processing and more recently in pharmaceutical and medical sciences. Pressure can stabilize enzymes and modulate both their activity and specificity. HP engineering of proteins may be used for enzyme-catalyzed synthesis of fine chemicals, pharmaceuticals, and production of
modified proteins of medical or pharmaceutical interest. HP inactivation of biological agents is expected to be applicable to sterilization of fragile biopharmaceuticals, or medical compounds. The enhanced immunogenicity of some pressure-killed bacteria and viruses could be applied for making new vaccines. Finally, storage at subzero temperatures without freezing is another potential application of HP for cells, animal tissues, blood cells, organs for transplant, and so forth.
Patent AT-E400382-T1: [Translated] DEVICE AND METHOD FOR CONTINUOUSLY FEEDING METAL MELTS UNDER PRESSURE

A molten metal supply system (90) includes a plurality of injectors (100) each having an injector housing (102) and a reciprocating piston (104). A molten metal supply source (132) is in fluid communication with the housing (102) of each of the injectors (100). The piston (104) is movable through a first stroke allowing molten metal (134) to be received into the housing (102) from the molten metal supply source (132), and a second stroke for displacing the molten metal (134) from the housing (102). A pressurized gas supply source (144) is in fluid communication with the housing (102) of each of the injectors (100) through respective gas control valves (146). The molten metal supply system (90) is in fluid communication with an outlet manifold (140) having a plurality of outlet dies (404), which may be used to form continuous metal articles including rods, bars, ingots, and continuous plate.
Compound 528788: 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16,18,18,20,20,22,22,24,24,26,26,28,28,30,30,32,32,34,34,36,36,38,38,40,40,42,42,44,44,46,46,48,48,50,50,52,52,54,54,56,56,58,58,60,60,62,62,64,64,66,66,68,68,70,70,72,72,74,74,76,76-Hexaheptacontameth

Chemical compound data from PubChem database. IUPAC Name: 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16,18,18,20,20,22,22,24,24,26,26,28,28,30,30,32,32,34,34,36,36,38,38,40,40,42,42,44,44,46,46,48,48,50,50,52,52,54,54,56,56,58,58,60,60,62,62,64,64,66,66,68,68,70,70,72,72,74,74,76,76-hexaheptacontamethyl-1,3,5,7,9,11,13,15,17,19,21,23,25,27,29,31,33,35,37,39,41,43,45,47,49,51,53,55,57,59,61,63,65,67,69,71,73,75-octatriacontaoxa-2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32,34,36,38,40,42,44,46,48,50,52,54,56,58,60,62,64,66,68,70,72,74,76-octatriacontasilacyclohexaheptacontane. Molecular Formula: C76H228O38Si38. Molecular Weight: 2817.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401507-T1: [Translated] CRANKSHAFT BEARING DEVICE

A Crankshaft bearing assembly for supporting a crankshaft for rotation about a crankshaft axis within an engine having an aluminum engine block, the crankshaft bearing assembly including at least one crankshaft bearing divided into a first half and a second half, the first half being integral with the engine block, and the second half being a bearing cap connectable to the engine block. The bearing cap is made of an aluminum alloy having a tensile strength higher than the tensile strength of the engine block.
2013 NSDUH Sample Size and Population Estimates Tables (Prevalence Estimates) - 8.1 to 8.13

These detailed tables show sample sizes and population estimates from the 2013 National Survey on Drug Use and Health (NSDUH). Samples sizes and population estimates are provided by age group, gender, race/ethnicity, education level, employment status, geographic area, pregnancy status, college enrollment status, and probation/parole status.
Compound 526405: 6-Bromo,1,2,4,8-tetrachloro-dibenzo-dioxin

Chemical compound data from PubChem database. IUPAC Name: 6-bromo-1,2,4,8-tetrachlorodibenzo-p-dioxin. Molecular Formula: C12H3BrCl4O2. Molecular Weight: 400.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Oriented antibody immobilization to polystyrene macrocarriers for immunoassay modified with hydrazide derivatives of poly(meth)acrylic acid

Background
          Hydrophobic polystyrene is the most common material for solid phase immunoassay. Proteins are immobilized on polystyrene by passive adsorption, which often causes considerable denaturation. Biological macromolecules were found to better retain their functional activity when immobilized on hydrophilic materials. Polyacrylamide is a common material for solid-phase carriers of biological macromolecules, including immunoreagents used in affinity chromatography. New macroformats for immunoassay modified with activated polyacrylamide derivatives seem to be promising.
        
        
          Results
          New polymeric matrices for immunoassay in the form of 0.63-cm balls which contain hydrazide functional groups on hydrophilic polymer spacer arms at their surface shell are synthesized by modification of aldehyde-containing polystyrene balls with hydrazide derivatives of poly(meth)acrylic acid. The beads contain up to 0.31 μmol/cm2 active hydrazide groups accessible for covalent reaction with periodate-oxidized antibodies. The matrices obtained allow carrying out the oriented antibody immobilization, which increases the functional activity of immunosorbents.
        
        
          Conclusions
          An efficient site-directed antibody immobilization on a macrosupport is realized. The polymer hydrophilic spacer arms are the most convenient and effective tools for oriented antibody coupling with molded materials. The suggested scheme can be used for the modification of any other solid supports containing electrophilic groups reacting with hydrazides.
Compound 526374: 1,2,6-Tribromo,3-chloro-dibenzo-dioxin

Chemical compound data from PubChem database. IUPAC Name: 1,2,6-tribromo-3-chlorodibenzo-p-dioxin. Molecular Formula: C12H4Br3ClO2. Molecular Weight: 455.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Behavioral Health Barometer: North Dakota, 2014

This is a behavioral health report for the state of North Dakota. It uses the  National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment, and medicare enrollees for the years 2009 to 2013.
VEHSS Medicare Fee for Service + Advantage (100%)

2021. This dataset is a de-identified summary table of vision and eye health data indicators from Medicare claims and encounters, stratified by all available combinations of age group, race/ethnicity, gender, and state. Medicare FFS + Advantage data for VEHSS includes beneficiaries who were fully enrolled in Medicare Part B (Fee-for-Service (FFS)) or Medicare Part C (Medicare Advantage) for the duration of the year. Medicare claims provide a convenience sample that is approximately representative of the US population aged 65 and older, and contains data for certain individuals younger than age 65 who are eligible for Medicare for other reasons, including disability due to blindness.  Medicare data for VEHSS include Service Utilization and Medical Diagnoses indicators. Data were suppressed for de-identification to ensure protection of patient privacy. Data will be updated as it becomes available. Historical data for Medicare FFS only is available on VEHSS from 2014.  Detailed information on VEHSS Medicare analyses can be found on the VEHSS Medicare webpage (cdc.gov/visionhealth/vehss/data/claims/medicare.html). Information on available Medicare claims data can be found on the ResDac website (www.resdac.org). The VEHSS Medicare dataset was last updated May 2025.
The National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) 

<p>The National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) is a national genetics data repository facilitating access to genotypic and phenotypic data for Alzheimer's disease (AD). Data include GWAS, whole genome (WGS) and whole exome (WES), expression, RNA Seq, and CHIP Seq analyses. Data for the Alzheimer’s Disease Sequencing Project (ADSP) are available through a partnership with dbGaP (ADSP at dbGaP). Results are integrated and annotated in the searchable genomics database that also provides access to a variety of software packages, analytic pipelines, online resources, and web-based tools to facilitate analysis and interpretation of large-scale genomic data. Data are available as defined by the NIA Genomics of Alzheimer’s Disease Sharing Policy and the NIH Genomics Data Sharing Policy. Investigators return secondary analysis data to the database in keeping with the NIAGADS Data Distribution Agreement.</p>
High affinity binding of proteins HMG1 and HMG2 to semicatenated DNA loops

Background
          Proteins HMG1 and HMG2 are two of the most abundant non histone proteins in the nucleus of mammalian cells, and contain a domain of homology with many proteins implicated in the control of development, such as the sex-determination factor Sry and the Sox family of proteins. In vitro studies of interactions of HMG1/2 with DNA have shown that these proteins can bind to many unusual DNA structures, in particular to four-way junctions, with binding affinities of 107 to 109 M-1.
        
        
          Results
          Here we show that HMG1 and HMG2 bind with a much higher affinity, at least 4 orders of magnitude higher, to a new structure, Form X, which consists of a DNA loop closed at its base by a semicatenated DNA junction, forming a DNA hemicatenane. The binding constant of HMG1 to Form X is higher than 5 × 1012 M-1, and the half-life of the complex is longer than one hour in vitro.
        
        
          Conclusions
          Of all DNA structures described so far with which HMG1 and HMG2 interact, we have found that Form X, a DNA loop with a semicatenated DNA junction at its base, is the structure with the highest affinity by more than 4 orders of magnitude. This suggests that, if similar structures exist in the cell nucleus, one of the functions of these proteins might be linked to the remarkable property of DNA hemicatenanes to associate two distant regions of the genome in a stable but reversible manner.
Compound 530252: 3-Isopropylcyclohexanol

Chemical compound data from PubChem database. IUPAC Name: 3-propan-2-ylcyclohexan-1-ol. Molecular Formula: C9H18O. Molecular Weight: 142.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - TABLE 1JJ. Tularemia to  Vancomycin-intermediate Staphylococcus aureus

NNDSS - TABLE 1JJ. Tularemia to  Vancomycin-intermediate Staphylococcus aureus - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Patent AT-E399581-T1: [Translated] COSMETIC PRODUCT CONTAINING PIGMENT WITH ANTI-AGING EFFECT FOR THE SKIN

Pigment containing cosmetic agent (A) with anti-aging effect for the skin, comprises active complex; carrier material; auxiliary material; and optionally further active agent, where the active complex comprises (wt.%): e.g. liposome encapsulated retinol (0.01-5) and retinyl palmitate (0.1-2) and a residue formed to 100 wt.% of carrier materials, auxiliary- and optionally further additives agent. Pigment containing cosmetic agent (A) with anti-aging effect on the skin, comprises active complex; carrier material; auxiliary material; and optionally further active agent, where the active material comprises (wt.%): liposome encapsulated retinol (0.01-5), retinyl palmitate (0.1-2), carbohydrate-rich, aqueous alfalfa extract (0.1-3), rock samphire extract (0.1-5) and layer pigment (0.01-5), comprising mica coated with titanium oxide/silicon dioxide and further titanium oxide layer and/or silicon dioxide-plate coated with rutile-titanium oxide; and a residue formed to 100 wt.% of carrier materials, auxiliary- and optionally further additives agent.
Water Quality Monitoring Sites

[<a href='https://files.hawaii.gov/dbedt/op/gis/data/wqm_sites.pdf' target='_blank' rel='nofollow ugc noopener noreferrer'>Metadata</a>]  Water Quality Monitoring Sites in Hawaii as of June, 2017.  Source:  Hawaii State Department of Health, Environmental Planning Office, June, 2017.  <span>This data
shows the location of water quality monitoring sites used by the Hawaii
Department of Health’s Clean Water Branch.</span><br /><div><br /></div><div>Please refer to metadata at <a href='https://files.hawaii.gov/dbedt/op/gis/data/wqm_sites.pdf' target='_blank' rel='nofollow ugc noopener noreferrer'>https://files.hawaii.gov/dbedt/op/gis/data/wqm_sites.pdf</a>.  </div><div><br /></div><div>For more information, contact Hawaii Statewide GIS Program, Office of Planning and Sustainable Development, State of Hawaii; PO Box 2359, Honolulu, HI 96804; (808) 587-2846; email: <a href='mailto:gis@hawaii.gov' target='_blank' rel='nofollow ugc noopener noreferrer'>gis@hawaii.gov</a>; Website: <a href='https://planning.hawaii.gov/gis/' target='_blank' rel='nofollow ugc noopener noreferrer'>https://planning.hawaii.gov/gis/</a>.</div>
ARCHIVED: Mpox Vaccinations Given to SF Residents by Demographics

<strong>In early February 2024, we will be retiring the Mpox Vaccinations Given to SF Residents by Demographics dataset. This dataset will be archived and no longer update. A historic record of this data will remain available.</strong>

<strong>A. SUMMARY </strong>
This dataset represents doses of mpox vaccine (JYNNEOS) administered in California to residents of San Francisco ages 18 years or older. This dataset only includes doses of the JYNNEOS vaccine given on or after 5/1/2022. All vaccines given to people who live in San Francisco are included, no matter where the vaccination took place. The data are broken down by multiple demographic stratifications.

<strong>B. HOW THE DATASET IS CREATED </strong>
Information on doses administered to those who live in San Francisco is from the <a href="https://cdph.ca.gov/CAIR">California Immunization Registry (CAIR2)</a>, run by the California Department of Public Health (CDPH). Information on individuals’ city of residence, age, race, ethnicity, and sex are recorded in CAIR2 and are self-reported at the time of vaccine administration. Because CAIR2 does not include information on sexual orientation, we pull information from the San Francisco Department of Public Health’s  Epic Electronic Health Record (EHR). The populations represented in our Epic data and the CAIR2 data are different. Epic data only include vaccinations administered at SFDPH managed sites to SF residents.  

Data notes for population characteristic types are listed below. 

<u>Age </u>
* Data only include individuals who are 18 years of age or older. 
 
<u>Race/ethnicity </u>
* The response option "Other Race" is categorized by the data source system, and the response option "Unknown" refers to a lack of data. 
 
<u>Sex </u>
* The response option "Other" is categorized by the source system, and the response option "Unknown" refers to a lack of data. 

<u>Sexual orientation </u>
* The response option “Unknown/Declined” refers to a lack of data or individuals who reported multiple different sexual orientations during their most recent interaction with SFDPH. 

For convenience, we provide <a href="https://data.sfgov.org/d/4qbq-hvtt"> the 2020 5-year American Community Survey population estimates</a>.

<strong>C. UPDATE PROCESS </strong>
Updated daily via automated process.

<strong>D. HOW TO USE THIS DATASET </strong>
This dataset includes many different types of demographic groups. Filter the “demographic_group” column to explore a topic area. Then, the “demographic_subgroup” column shows each group or category within that topic area and the total count of doses administered to that population subgroup.

<strong>E. CHANGE LOG</strong>
<ul><li>UPDATE 1/3/2023: Due to low case numbers, this page will no longer include vaccinations after 12/31/2022.</li></ul>
Compound 528592: Benzenepropanoic acid, alpha-[(tert-butyldimethylsilyl)oxy]-, tert-butyldimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 2-[tert-butyl(dimethyl)silyl]oxy-3-phenylpropanoate. Molecular Formula: C21H38O3Si2. Molecular Weight: 394.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527501: 11-nor-D9-Tetrahydrocannabinol-9-carboxylic acid

Chemical compound data from PubChem database. IUPAC Name: 1-hydroxy-6-methyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene-9-carboxylic acid. Molecular Formula: C20H26O4. Molecular Weight: 330.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399908-T1: [Translated] CONCRETE FLOOR ELEMENT

The floor part has intermediate parts (3) that connect a bottom plate and a top plate (2a). The intermediate parts are continuous in two directions that are transverse to each other, for defining girders with the plates for bearing span in both directions. The intermediate parts define passages for connecting the cavities defined by girders, with each other in one direction. Independent claims are also included for the following: (a) a building having a floor built up from concrete floor parts (b) a method for manufacturing a concrete floor part.
Patent AT-E399723-T1: [Translated] VALVE STEM FOR A DOSING VALVE

A valve stem ( 100 ) for use with a metered dose dispensing valve, said valve stem having a central longitudinal axis and comprising a first stem portion ( 101 ), a second stem portion ( 102 ) and a disk seal ( 112 ), said disk seal being disposed between the first and second stem portion along the longitudinal axis of the valve stem and said disk seal extending radially outwardly from the central longitudinal axis of valve stem so as to be capable of forming a fluid-tight seal with a portion of an internal wall of said valve.
A comprehensive analysis of 40 blind protein structure predictions

Background
          We thoroughly analyse the results of 40 blind predictions for which an experimental answer was made available at the fourth meeting on the critical assessment of protein structure methods (CASP4). Using our comparative modelling and fold recognition methodologies, we made 29 predictions for targets that had sequence identities ranging from 50% to 10% to the nearest related protein with known structure. Using our ab initio methodologies, we made eleven predictions for targets that had no detectable sequence relationships. 
        
        
          Results
          For 23 of these proteins, we produced models ranging from 1.0 to 6.0 Å root mean square deviation (RMSD) for the Cα atoms between the model and the corresponding experimental structure for all or large parts of the protein, with model accuracies scaling fairly linearly with respect to sequence identity (i.e., the higher the sequence identity, the better the prediction). We produced nine models with accuracies ranging from 4.0 to 6.0 Å Cα RMSD for 60–100 residue proteins (or large fragments of a protein), with a prediction accuracy of 4.0 Å Cα RMSD for residues 1–80 for T110/rbfa.
        
        
          Conclusions
          The areas of protein structure prediction that work well, and areas that need improvement, are discernable by examining how our methods have performed over the past four CASP experiments. These results have implications for modelling the structure of all tractable proteins encoded by the genome of an organism.
Compound 528590: Pentanoic acid, 5-phenyl, TBDMS

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 5-phenylpentanoate. Molecular Formula: C17H28O2Si. Molecular Weight: 292.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Outpatient and Ambulatory Surgery Consumer Assessment of Healthcare Providers and Systems (OAS CAHPS) survey for hospital outpatient departments - National

The file contains the national average for the OAS CAHPS survey responses. The OAS CAHPS survey collects information about patients' experiences of care in hospital outpatient departments (HOPDs) and ambulatory surgical centers (ASCs). The data are updated and reported each quarter with data from the most recently completed quarter replacing the oldest quarter of data.
Compound 529422: 1(2H)-Naphthalenone, 2-methyl

Chemical compound data from PubChem database. IUPAC Name: 2-methyl-2H-naphthalen-1-one. Molecular Formula: C11H10O. Molecular Weight: 158.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.